What is China Biologic Products Holdings EV-to-EBITDA?
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, China Biologic Products Holdings's enterprise value is $3,640.3 Mil.
China Biologic Products Holdings's EBITDA for the trailing twelve months (TTM) ended in Sep. 2020 was $225.9 Mil. Therefore, China Biologic Products Holdings's EV-to-EBITDA for today is 16.12.
The historical rank and industry rank for China Biologic Products Holdings's EV-to-EBITDA or its related term are showing as below:
CBPO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.46 Med: 15.07 Max: 19.13
Current: 16.12
During the past 13 years, the highest EV-to-EBITDA of China Biologic Products Holdings was 19.13. The lowest was 9.46. And the median was 15.07.
CBPO's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.49
vs CBPO: 16.12
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
China Biologic Products Holdings EV-to-EBITDA Chart
Competitive Comparison of China Biologic Products Holdings's EV-to-EBITDA
For the Biotechnology subindustry, China Biologic Products Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Biologic Products Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, China Biologic Products Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where China Biologic Products Holdings's EV-to-EBITDA falls into.
China Biologic Products Holdings EV-to-EBITDA Calculation
China Biologic Products Holdings's current Enterprise Value is $3,640.3 Mil.
China Biologic Products Holdings's EBITDA for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $225.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biologic Products Holdings (NAS:CBPO) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
China Biologic Products Holdings's PE Ratio for today is calculated as:
China Biologic Products Holdings's share price for today is $119.99.
China Biologic Products Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
China Biologic Products Holdings EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of China Biologic Products Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
China Biologic Products Holdings (China Biologic Products Holdings) Business Description
China Biologic Products Holdings Inc is a biopharmaceutical company principally engaged in the research, development, manufacturing and sales of human plasma-based products in China. The company operates its business through two majority owned subsidiaries, Shandong Taibang and Guizhou Taibang. China Biologic's product pipeline includes a variety of dosages across multiple product categories. Its principal products are human albumin and immunoglobulin for intravenous injection. All of the company's products are prescription medicines administered in the form of injections. China Biologic's sales model focuses on direct sales to hospitals and inoculation centers and is complemented by distributor sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CBPO has been successfully added to your 